A Phase 2 interventional study of Sodium bicarbonate plus sodium fluoride and Sodium fluoride in Oral Hygiene, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-13.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objectives of this study will be to compare the Gingival Bleeding and Gingival Inflammation following twice daily use of a sodium bicarbonate experimental dentifrice compared to a 0% sodium bicarbonate toothpaste after 24 weeks of use. The study will be conducted at Silverstone Research Group. Participants will be recruited from their database and by use of an external recruitment agency.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
Drug: Sodium bicarbonate plus sodium fluoride
Toothpaste containing 1100 ppm fluoride as sodium fluoride
Drug: Sodium fluoride
Drug pages: Sodium Bicarbonate · Sodium Fluoride
Experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
Toothpaste containing 1100 ppm fluoride as sodium fluoride
Number of Gingival Bleeding Sites at 24 Weeks
Number of gingival bleeding sites were measured as bleeding index via a single examiner using a color coded periodontal probe. The probe was engaged approximately 1 millimetre (mm) into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system used to measure bleeding sites is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed. A bleeding site was considered as a BI score of 1 or 2.
Time frame: Baseline, 24 weeks
Modified Gingival Index (MGI) at 24 Weeks
The Modified Gingival Index (MGI) was assessed on facial and lingual surfaces at two sites on each tooth (papillae and margin). The scoring of the MGI was performed under dental office conditions using a standard dental light for illuminating the oral cavity. Compressed air, water and mouth mirrors were available to each examiner. This procedure was performed by a single examiner. The MGI scoring system is as follows: 0 = absence of inflammation; 1 = mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit; 2 = mild inflammation; criteria as above but involving the entire marginal or papillar gingival units; 3= moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit; 4 = severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration
Time frame: Baseline, 24 weeks
Number of Gingival Bleeding Sites at 6 and 12 Weeks.
Number of gingival bleeding sites were measured as bleeding index via a single examiner using a color coded periodontal probe. The probe was engaged approximately 1 millimetre (mm) into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system used to measure bleeding sites is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed. A bleeding site was considered as a BI score of 1 or 2.
Time frame: Baseline, 6 and 12 weeks
Modified Gingival Index (MGI) at 6 and 12 Weeks.
MGI was assessed on facial and lingual surfaces at two sites on each tooth (papillae and margin). The scoring of the MGI was performed under dental office conditions using a standard dental light for illuminating the oral cavity. Compressed air, water and mouth mirrors were available to each examiner. This procedure was performed by a single examiner. The MGI scoring system is as follows: 0 = absence of inflammation; 1 = mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit; 2 = mild inflammation; criteria as above but involving the entire marginal or papillar gingival units; 3= moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit; 4 = severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration
Time frame: Baseline, 6 and 12 weeks
Bleeding Index at 6, 12 and 24 Weeks
The Bleeding Index was performed by a single examiner using a color coded periodontal probe. The probe was engaged approximately 1 millimetre (mm) into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system to be used is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed
Time frame: Baseline, 6, 12 and 24 weeks
Plaque Control (Overall and Interproximal Dental Plaque Scores) Using Turesky Modification of Quigley &Amp; Hein Plaque Index at 6, 12 and 24 Weeks.
The dental examiner used the Turesky Modification of the Quigley Hein Index to assess plaque on all gradable teeth. The plaque was first disclosed using a dye solution. Participants then rinsed with disclosing solution according to instructions. They had expectorated and rinsed with 10 mL of water for 10 seconds and expectorated again. Plaque was assessed with each tooth being divided into 6 areas including the mesiofacial, facial, distofacial, mesiolingual, lingual and distolingual surfaces. Disclosed plaque was scored as follows: 0= No plaque; 1= Slight flecks of plaque at the cervical margin of the tooth; 2= A thin continuous band of plaque (1 mm or smaller) at the cervical margin of the tooth; 3= A band of plaque wider than 1 mm but covering less than 1/3 of the crown of the tooth; 4= Plaque covering at least 1/3 but less tan 2/3 of the crown of the tooth; 5= Plaque covering 2/3 or more of the crown of the tooth
Time frame: Baseline, 6,12 and 24 weeks
The participants were recruited at a clinical site in the USA.
| Milestone | Sodium Bicarbonate Dentrifice | 0% Sodium Bicarbonate Dentrifice |
|---|---|---|
| Started | 124 | 123 |
| Completed | 113 | 115 |
| Not completed | 11 | 8 |
| Withdrew: Lost to follow-up | 3 | 1 |
| Withdrew: Withdrawal by subject | 5 | 6 |
| Withdrew: Did not meet study criteria | 3 | 0 |
| Withdrew: Pregnancy | 0 | 1 |
Number of gingival bleeding sites were measured as bleeding index via a single examiner using a color coded periodontal probe. The probe was engaged approximately 1 millimetre (mm) into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system used to measure bleeding sites is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed. A bleeding site was considered as a BI score of 1 or 2.
| number of gingival bleeding sites | Sodium Bicarbonate Dentrifice | 0% Sodium Bicarbonate Dentrifice |
|---|---|---|
| Number of Bleeding Sites at Baseline | 45.13 ± 1.393 | 45.84 ± 1.448 |
| Number of Bleeding sites after 24 weeks | 18.67 ± 1.142 | 36.39 ± 1.510 |
The Modified Gingival Index (MGI) was assessed on facial and lingual surfaces at two sites on each tooth (papillae and margin). The scoring of the MGI was performed under dental office conditions using a standard dental light for illuminating the oral cavity. Compressed air, water and mouth mirrors were available to each examiner. This procedure was performed by a single examiner. The MGI scoring system is as follows: 0 = absence of inflammation; 1 = mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit; 2 = mild inflammation; criteria as above but involving the entire marginal or papillar gingival units; 3= moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit; 4 = severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration
| Units on a scale | Sodium Bicarbonate Dentrifice | 0% Sodium Bicarbonate Dentrifice |
|---|---|---|
| Modified Gingival Index at Baseline | 2.53 ± 0.017 | 2.54 ± 0.018 |
| Modified Gingival Index after 24 weeks | 2.23 ± 0.021 | 2.43 ± 0.210 |
Number of gingival bleeding sites were measured as bleeding index via a single examiner using a color coded periodontal probe. The probe was engaged approximately 1 millimetre (mm) into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system used to measure bleeding sites is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed. A bleeding site was considered as a BI score of 1 or 2.
| number of gingival bleeding sites | Sodium Bicarbonate Dentrifice | 0% Sodium Bicarbonate |
|---|---|---|
| Number of Bleeding Sites at Baseline | 45.13 ± 1.393 | 45.84 ± 1.448 |
| Number of Bleeding Sites after 6 weeks | 25.40 ± 0.999 | 40.27 ± 1.448 |
| Number of Bleeding sites after 12 weeks | 20.83 ± 0.915 | 34.23 ± 1.260 |
MGI was assessed on facial and lingual surfaces at two sites on each tooth (papillae and margin). The scoring of the MGI was performed under dental office conditions using a standard dental light for illuminating the oral cavity. Compressed air, water and mouth mirrors were available to each examiner. This procedure was performed by a single examiner. The MGI scoring system is as follows: 0 = absence of inflammation; 1 = mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit; 2 = mild inflammation; criteria as above but involving the entire marginal or papillar gingival units; 3= moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit; 4 = severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration
| Units on a scale | Sodium Bicarbonate Dentrifice | 0% Sodium Bicarbonate Dentrifice |
|---|---|---|
| Modified Gingival Index at Baseline | 2.53 ± 0.017 | 2.54 ± 0.018 |
| Modified Gingival Index after 6 weeks | 2.28 ± 0.017 | 2.45 ± 0.018 |
| Modified Gingival Index after 12 weeks | 2.24 ± 0.018 | 2.40 ± 0.018 |
The Bleeding Index was performed by a single examiner using a color coded periodontal probe. The probe was engaged approximately 1 millimetre (mm) into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system to be used is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed
| Units on a Scale | Sodium Bicarbonate Dentrifice | 0% Sodium Bicarbonate Dentrifice |
|---|---|---|
| Bleeding Index Score at Baseline | 0.45 ± 0.014 | 0.47 ± 0.014 |
| Bleeding Index Score after 6 weeks | 0.25 ± 0.010 | 0.41 ± 0.014 |
| Bleeding Index Score after 12 weeks | 0.21 ± 0.009 | 0.35 ± 0.012 |
| Bleeding Index Score after 24 weeks | 0.19 ± 0.012 | 0.37 ± 0.014 |
The dental examiner used the Turesky Modification of the Quigley Hein Index to assess plaque on all gradable teeth. The plaque was first disclosed using a dye solution. Participants then rinsed with disclosing solution according to instructions. They had expectorated and rinsed with 10 mL of water for 10 seconds and expectorated again. Plaque was assessed with each tooth being divided into 6 areas including the mesiofacial, facial, distofacial, mesiolingual, lingual and distolingual surfaces. Disclosed plaque was scored as follows: 0= No plaque; 1= Slight flecks of plaque at the cervical margin of the tooth; 2= A thin continuous band of plaque (1 mm or smaller) at the cervical margin of the tooth; 3= A band of plaque wider than 1 mm but covering less than 1/3 of the crown of the tooth; 4= Plaque covering at least 1/3 but less tan 2/3 of the crown of the tooth; 5= Plaque covering 2/3 or more of the crown of the tooth
| Units on a scale | Sodium Bicarbonate Dentrifice | 0% Sodium Bicarbonate Dentrifice |
|---|---|---|
| Overall Plaque Score at Baseline | 3.04 ± 0.019 | 3.00 ± 0.019 |
| Overall Plaque Score after 6 weeks | 2.65 ± 0.030 | 2.98 ± 0.021 |
| Overall Plaque Score after 12 weeks | 2.55 ± 0.029 | 2.92 ± 0.025 |
| Overall Plaque Score after 24 weeks | 2.52 ± 0.032 | 2.95 ± 0.020 |
| Interproximal Plaque Score at Baseline | 3.12 ± 0.019 | 3.08 ± 0.018 |
| Interproximal Plaque Score after 6 weeks | 2.73 ± 0.029 | 3.05 ± 0.020 |
| Interproximal Plaque Score after 12 weeks | 2.64 ± 0.028 | 3.01 ± 0.022 |
| Interproximal Plaque Score after 24 weeks | 2.61 ± 0.031 | 3.03 ± 0.019 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sodium Bicarbonate Dentrifice | — | 0/124 (0%) | 7/124 (5.6%) |
| 0% Sodium Bicarbonate Dentrifice | — | 0/123 (0%) | 8/123 (6.5%) |
| Event | Sodium Bicarbonate Dentrifice | 0% Sodium Bicarbonate Dentrifice |
|---|---|---|
| MOUTH INJURYInjury, poisoning and procedural complications | 3/124 | 3/123 |
| PROCEDURAL PAINInjury, poisoning and procedural complications | 1/124 | 1/123 |
| THERMAL BURNInjury, poisoning and procedural complications | 1/124 | 1/123 |
| NASOPHARYNGITISInfections and infestations | 0/124 | 1/123 |
| ABDOMINAL PAINGastrointestinal disorders | 0/124 | 1/123 |
| GINGIVAL PAINGastrointestinal disorders | 0/124 | 1/123 |
| SENSITIVITY OF TEETHGastrointestinal disorders | 0/124 | 1/123 |
| BRONCHITISInfections and infestations | 1/124 | 0/123 |
| OVARIAN CYST RUPTUREDRespiratory, thoracic and mediastinal disorders | 1/124 | 0/123 |
| Age, Continuous(Years) | Sodium Bicarbonate Dentrifice | 0% Sodium Bicarbonate Dentrifice | Total |
|---|---|---|---|
| Mean | 34.52 ± 13.162 | 37.55 ± 13.977 | 36.03 ± 13.631 |
| Sex: Female, Male(Participants) | Sodium Bicarbonate Dentrifice | 0% Sodium Bicarbonate Dentrifice | Total |
|---|---|---|---|
| Female | 69 | 72 | 141 |
| Male | 55 | 51 | 106 |
The record gives a start of Aug 2014, a primary completion of Feb 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2017, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sodium Bicarbonate · Sodium Fluoride